Patient-reported Outcomes After Prostate Stereotactic Body Radiotherapy at 5 yr: Results from the PACE-B Trial

Genitourinary Cancer

10-yr Survival and Toxicity Outcomes of Stereotactic Body Radiotherapy for Prostate Cancer: A Nonrandomized Clinical Trial

Eur Urol

Meier RM, Aghdam N, Beckman AC, Woodhouse SA, Williamson SK, Mohideen N, Dombrowski JJ, Kaplan ID

doi: 10.1016/j.eururo.2026.04.029

Genitourinary Cancer

Exploring Factors Associated with Late Urinary Toxicity After Prostate Stereotactic Body Radiotherapy: Findings from the PACE-B Study

Eur Urol

Ratnakumaran R, Brand DH, Sasitharan A, Mohajer J, Hinder V, Khan A, Mayet H, Loblaw A, Hall E, van As N, Tree AC, PACE Trial Investigators

doi: 10.1016/j.eururo.2025.07.007

Genitourinary Cancer

Ultra-hypofractionated stereotactic ablative body radiotherapy for primary renal cell carcinoma: 5-year outcomes from a pooled analysis of the FASTRACK trials

Lancet Oncol

Siva S, Ali M, Hardcastle N, Kron T, Higgs B, Foroudi F, Ruben J, Appu S, Martin J, Sridharan S, Montgomery R, Davey R, Lin C, Shaw M, Chander S, Sidhom M, Vanneste BGL, Murphy DG, Lawrentschuk N, Pryor D, Wood S, Moon D, Bressel M

doi: 10.1016/S1470-2045(26)00170-1

SPECIAL REPORT

Genitourinary Cancer

Insights from the EMBARK Trial: Identifying Eligible Patients for Optimized Outcomes

Leukemia

Venetoclax combinations in untreated CLL: 5-year results and patient-reported outcome analysis of the CLL13/GAIA trial

Blood

Fürstenau M, Niemann CU, Robrecht S, Rotbain EC, Eurelings LEM, Giza A, von Tresckow J, Zhang C, Gregor M, Thornton P, Staber PB, Tadmor T, Lindstrom V, Juliusson G, Janssens A, da Cunha-Bang C, Schneider C, Herishanu Y, O'Shea D, Baumann M, Widmer AA, Nösslinger T, Bjørn Poulsen C, Frederiksen H, Lotfi K, Ranti J, Enggaard L, Velders GA, Vekemans MM, de Heer K, Snijders TJF, Siemes C, Wendtner CM, Knauf WU, Kroeber A, Zahn MO, Illmer T, Schöttker B, Simon F, Fink AM, Fischer K, D'Brot R, Holmes EE, Kreuzer KA, Ritgen M, Brüggemann M, Tausch E, Stilgenbauer S, Levin MD, Hallek MJ, Kater AP, Eichhorst BF

doi: 10.1182/blood.2025032160

Genitourinary Cancer

Focal Boost to the Intraprostatic Tumor in External Beam Radiotherapy for Patients With Localized Prostate Cancer: 10-Year Outcomes of the FLAME Trial

J Clin Oncol

Menne Guricová K, Draulans C, Pos FJ, Kerkmeijer LGW, Monninkhof EM, Smeenk RJ, Kunze-Busch M, de Boer HCJ, van der Voort van der Zyp JRN, Haustermans K, van der Heide UA

doi: 10.1200/JCO-25-00274

Lung, Respiratory and Thoracic Cancer

Patient-reported EORTC QLQ C-30 global health status decline predicts survival after video-assisted thoracoscopic (VATS) lung resection and stereotactic ablative radiotherapy (SABR): A 5 year follow-up from the Lilac study

Lung Cancer

Pompili C, Jaques L, Callister MEJ, Franks KN, Brunelli A, Velikova G

doi: 10.1016/j.lungcan.2026.109335

Genitourinary Cancer

Ultra-hypofractionated versus conventionally fractionated radiotherapy for localised prostate cancer (HYPO-RT-PC): 10-year outcomes of an open-label, randomised, phase 3, non-inferiority trial

Lancet Oncol

Nilsson P, Gunnlaugsson A, Beckman L, Widmark A, Fransson P, Hoyer M, Lagerlund M, Kindblom J, Johansson B, Björnlinger K, Ginman C, Olsson M, Agrup M, Kjellén E, Zackrisson B, Tavelin B, Franzén L, Anderson H, Thellenberg Karlsson C

doi: 10.1016/S1470-2045(25)00656-4

Multiple Myeloma (MM)

Patient-reported outcomes with belantamab mafodotin, pomalidomide, and dexamethasone versus bortezomib, pomalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-8): a phase 3, open-label, randomised controlled trial

Lancet Haematol

Dimopoulos MA, Beksac M, Pour L, Delimpasi S, Vorobyev V, Quach H, Spicka I, Radocha J, Robak P, Kim K, Cavo M, Suzuki K, Wilkes J, McNamara S, Phillips-Jones A, Morris K, Pompilus F, Purser M, Sule N, Kremer B, Loubert A, Bunod L, M'Hari M, Zhou XL, Fulci G, Mateos MV, Trudel S, DREAMM-8 investigators

doi: 10.1016/S2352-3026(25)00256-X

Related content

10-yr Survival and Toxicity Outcomes of Stereotactic Body Radiotherapy for Prostate Cancer: A Nonrandomized Clinical Trial

Exploring Factors Associated with Late Urinary Toxicity After Prostate Stereotactic Body Radiotherapy: Findings from the PACE-B Study

Ultra-hypofractionated stereotactic ablative body radiotherapy for primary renal cell carcinoma: 5-year outcomes from a pooled analysis of the FASTRACK trials

Insights from the EMBARK Trial: Identifying Eligible Patients for Optimized Outcomes

Venetoclax combinations in untreated CLL: 5-year results and patient-reported outcome analysis of the CLL13/GAIA trial

Focal Boost to the Intraprostatic Tumor in External Beam Radiotherapy for Patients With Localized Prostate Cancer: 10-Year Outcomes of the FLAME Trial

Patient-reported EORTC QLQ C-30 global health status decline predicts survival after video-assisted thoracoscopic (VATS) lung resection and stereotactic ablative radiotherapy (SABR): A 5 year follow-up from the Lilac study

Ultra-hypofractionated versus conventionally fractionated radiotherapy for localised prostate cancer (HYPO-RT-PC): 10-year outcomes of an open-label, randomised, phase 3, non-inferiority trial

Patient-reported outcomes with belantamab mafodotin, pomalidomide, and dexamethasone versus bortezomib, pomalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-8): a phase 3, open-label, randomised controlled trial